Literature DB >> 11788236

GSK-3 and the neurodevelopmental hypothesis of schizophrenia.

Nitsan Kozlovsky1, R H Belmaker, Galila Agam.   

Abstract

The Neurodevelopmental Hypothesis of schizophrenia suggests that interaction between genetic and environmental events occurring during critical early periods in neuronal growth may negatively influence the way by which nerve cells are laid down, differentiated and selectively culled by apoptosis. Recent advances offer insights into the regulation of brain development. The Wnt family of genes plays a central role in normal brain development. Activation of the Wnt cascade leads to inactivation of glycogen synthase kinase-3beta (GSK-3beta), accumulation and activation of beta-catenin and expression of genes involved in neuronal development. Alteration in the Wnt transduction cascade, which may represent an aberrant neurodevelopment in schizophrenia, is discussed. Programmed cell death is also an essential component of normal brain development. Abnormal neuronal distribution found in schizophrenic patients' brains may imply aberrant programmed cell death. GSK-3 participates in the signal transduction cascade of apoptosis. The possible role of aberrant GSK-3 in the etiology of schizophrenia is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788236     DOI: 10.1016/s0924-977x(01)00131-6

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  44 in total

Review 1.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 2.  Winding through the WNT pathway during cellular development and demise.

Authors:  F Li; Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2006-01       Impact factor: 2.303

Review 3.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

4.  Differences in 5-HT2A and mGlu2 Receptor Expression Levels and Repressive Epigenetic Modifications at the 5-HT2A Promoter Region in the Roman Low- (RLA-I) and High- (RHA-I) Avoidance Rat Strains.

Authors:  Luna Fomsgaard; Jose L Moreno; Mario de la Fuente Revenga; Tomasz Brudek; Dea Adamsen; Cristobal Rio-Alamos; Justin Saunders; Anders Bue Klein; Ignasi Oliveras; Toni Cañete; Gloria Blazquez; Adolf Tobeña; Albert Fernandez-Teruel; Javier Gonzalez-Maeso; Susana Aznar
Journal:  Mol Neurobiol       Date:  2017-03-06       Impact factor: 5.590

Review 5.  The role of GSK-3 in synaptic plasticity.

Authors:  S Peineau; C Bradley; C Taghibiglou; A Doherty; Z A Bortolotto; Y T Wang; G L Collingridge
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

6.  GSK3β Hyperactivity during an Early Critical Period Impairs Prefrontal Synaptic Plasticity and Induces Lasting Deficits in Spine Morphology and Working Memory.

Authors:  Bo Xing; Yan-Chun Li; Wen-Jun Gao
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

7.  Alternative complement pathway in schizophrenia.

Authors:  Anna Boyajyan; Aren Khoyetsyan; Andranik Chavushyan
Journal:  Neurochem Res       Date:  2010-01-26       Impact factor: 3.996

Review 8.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

9.  An Association Study Between Genetic Polymorphisms in Functional Regions of Five Genes and the Risk of Schizophrenia.

Authors:  Peng Yan; Xiaomeng Qiao; Hua Wu; Fangyuan Yin; Jing Zhang; Yuanyuan Ji; Shuguang Wei; Jianghua Lai
Journal:  J Mol Neurosci       Date:  2016-04-07       Impact factor: 3.444

10.  The activation of the Akt/PKB signalling pathway in the brains of clozapine-exposed rats is linked to hyperinsulinemia and not a direct drug effect.

Authors:  G C Smith; H McEwen; J D Steinberg; P R Shepherd
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.